i have a patient i want to start on Glow

To start a patient on Glow, which appears to involve the use of BPC-157, you should consider the following information: 1. **BPC-157 Overview**: BPC-157 is a synthetic pentadecapeptide derived from human gastric juice, primarily studied in preclinical models. It has shown potential benefits in promoting angiogenesis, modulating growth factor pathways, and enhancing tissue repair, particularly in tendon, ligament, muscle, and gastrointestinal tissues [1]. 2. **Dosing Protocol**: For tissue repair and recovery, a common dosing protocol for BPC-157 is 250 mcg subcutaneously twice daily for 4 weeks, followed by 250 mcg once daily for maintenance. It is important to reconstitute BPC-157 with bacteriostatic water and refrigerate after mixing [5]. 3. **Safety and Monitoring**: Human safety data for BPC-157 are limited, and it is not approved as a drug in many regions. Mild reactions at injection sites may occur. It is advisable to monitor inflammatory markers, including hs-CRP, at baseline and every 4 weeks during treatment [5]. 4. **Combination with Other Agents**: BPC-157 may be combined with TB-500 (2 mg subcutaneously twice weekly for 6 weeks) to support connective tissue and tendon recovery. Caution is advised in patients with active malignancy [5]. 5. **Regulatory Considerations**: The regulatory status of BPC-157 varies by jurisdiction, and sourcing and purity are practical concerns. Claims regarding its efficacy should be framed as preclinical and hypothesis-generating due to the thin human evidence base [1]. Please remember that this information is for decision support only and not a directive. Always use your clinical judgment when considering treatment options.